These results highlight the potential importance of non-fibrillar oligomeric tau species in AD pathogenesis and suggest that some therapeutic approaches targeting fibrillar conformations may miss the equally (or perhaps more) bioactive HMW oligomeric species. This evidence concerns the gene MAPT and Alzheimer disease.